Literature DB >> 26566760

Craniosynostosis in 10q26 deletion patients: A consequence of brain underdevelopment or altered suture biology?

Ágatha Cristhina Faria1,2, Eliete Rabbi-Bortolini3, Maria R G O Rebouças4, Andréia L A de S Thiago Pereira5, Milena G Tonini Frasson5, Rodrigo Atique6, Naila Cristina V Lourenço6, Carla Rosenberg6, Gerson S Kobayashi6, Maria Rita Passos-Bueno6, Flávia Imbroisi Valle Errera1,2.   

Abstract

Approximately a hundred patients with terminal 10q deletions have been described. They present with a wide range of clinical features always accompanied by delayed development, intellectual disability and craniofacial dysmorphisms. Here, we report a girl and a boy with craniosynostosis, developmental delay and other congenital anomalies. Karyotyping and molecular analysis including Multiplex Ligation dependent probe amplification (MLPA) and Array Comparative Genomic Hybridization (aCGH) were performed in both patients. We detected a 13.1 Mb pure deletion at 10q26.12-q26.3 in the girl and a 10.9 Mb pure deletion at 10q26.13-q26.3 in the boy, both encompassing about 100 genes. The clinical and molecular findings in these patients reinforce the importance of the DOCK1 smallest region of overlap I (SRO I), previously suggested to explain the clinical signs, and together with a review of the literature suggest a second 3.5 Mb region important for the phenotype (SRO II). Genotype-phenotype correlations and literature data suggest that the craniosynostosis is not directly related to dysregulated signaling in suture development, but may be secondary to alterations in brain development instead. Further, genes at 10q26 may be involved in the molecular crosstalk between brain and cranial vault.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  10q26; EBF3; HMX2; HMX3; array CGH; brain development; craniofacial dysmorphisms; synostosis

Mesh:

Year:  2015        PMID: 26566760     DOI: 10.1002/ajmg.a.37448

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  Novel de novo variant in EBF3 is likely to impact DNA binding in a patient with a neurodevelopmental disorder and expanded phenotypes: patient report, in silico functional assessment, and review of published cases.

Authors:  Patrick R Blackburn; Sarah S Barnett; Michael T Zimmermann; Margot A Cousin; Charu Kaiwar; Filippo Pinto E Vairo; Zhiyv Niu; Matthew J Ferber; Raul A Urrutia; Duygu Selcen; Eric W Klee; Pavel N Pichurin
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-05

2.  Lessons learned from additional research analyses of unsolved clinical exome cases.

Authors:  Mohammad K Eldomery; Zeynep Coban-Akdemir; Tamar Harel; Jill A Rosenfeld; Tomasz Gambin; Asbjørg Stray-Pedersen; Sébastien Küry; Sandra Mercier; Davor Lessel; Jonas Denecke; Wojciech Wiszniewski; Samantha Penney; Pengfei Liu; Weimin Bi; Seema R Lalani; Christian P Schaaf; Michael F Wangler; Carlos A Bacino; Richard Alan Lewis; Lorraine Potocki; Brett H Graham; John W Belmont; Fernando Scaglia; Jordan S Orange; Shalini N Jhangiani; Theodore Chiang; Harsha Doddapaneni; Jianhong Hu; Donna M Muzny; Fan Xia; Arthur L Beaudet; Eric Boerwinkle; Christine M Eng; Sharon E Plon; V Reid Sutton; Richard A Gibbs; Jennifer E Posey; Yaping Yang; James R Lupski
Journal:  Genome Med       Date:  2017-03-21       Impact factor: 11.117

3.  De novo variants in EBF3 are associated with hypotonia, developmental delay, intellectual disability, and autism.

Authors:  Akemi J Tanaka; Megan T Cho; Rebecca Willaert; Kyle Retterer; Yuri A Zarate; Katie Bosanko; Vikki Stefans; Kimihiko Oishi; Amy Williamson; Golder N Wilson; Alice Basinger; Tina Barbaro-Dieber; Lucia Ortega; Susanna Sorrentino; Melissa K Gabriel; Ilse J Anderson; Maria J Guillen Sacoto; Rhonda E Schnur; Wendy K Chung
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-11-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.